Terms: = Bone cancer AND MECOM, MDS1-EVI1, EVI1, 2122, ENSG00000085276, Q03112, PRDM3 AND Treatment
22 results:
1. Classical cannabinoid receptors as target in cancer-induced bone pain: a systematic review, meta-analysis and bioinformatics validation.
Zeng F; Wade A; Harbert K; Patel S; Holley JS; Dehghanpuor CK; Hopwood T; Marino S; Sophocleous A; Idris AI
Sci Rep; 2024 Mar; 14(1):5782. PubMed ID: 38461339
[TBL] [Abstract] [Full Text] [Related]
2. Efficacy of novel agents against cellular models of familial platelet disorder with myeloid malignancy (FPD-MM).
Mill CP; Fiskus WC; DiNardo CD; Reville P; Davis JA; Birdwell CE; Das K; Hou H; Takahashi K; Flores L; Ruan X; Su X; Loghavi S; Khoury JD; Bhalla KN
Blood Cancer J; 2024 Feb; 14(1):25. PubMed ID: 38316746
[TBL] [Abstract] [Full Text] [Related]
3. Reduced-intensity conditioning is effective for allogeneic hematopoietic stem cell transplantation in infants with mecom-associated syndrome.
Irie M; Niihori T; Nakano T; Suzuki T; Katayama S; Moriya K; Niizuma H; Suzuki N; Saito-Nanjo Y; Onuma M; Rikiishi T; Sato A; Hangai M; Hiwatari M; Ikeda J; Tanoshima R; Shiba N; Yuza Y; Yamamoto N; Hashii Y; Kato M; Takita J; Maeda M; Aoki Y; Imaizumi M; Sasahara Y
Int J Hematol; 2023 Apr; 117(4):598-606. PubMed ID: 36515795
[TBL] [Abstract] [Full Text] [Related]
4. Pubectomy and urinary reconstruction provides definitive treatment of urosymphyseal fistula following prostate cancer treatment.
Andrews JR; Hebert KJ; Boswell TC; Avant RA; Boonipatt T; Kreutz-Rodrigues L; Bakri K; Houdek MT; Karnes RJ; Viers BR
BJU Int; 2021 Oct; 128(4):460-467. PubMed ID: 33403768
[TBL] [Abstract] [Full Text] [Related]
5. Targeted RNA-Sequencing Enables Detection of Relevant Translocations and Single Nucleotide Variants and Provides a Method for Classification of Hematological Malignancies-RANKING.
de Lange K; de Boer EN; Bosga A; Alimohamed MZ; Johansson LF; Mulder AB; Vellenga E; van Diemen CC; Deelen P; van den Berg E; Sikkema-Raddatz B
Clin Chem; 2020 Dec; 66(12):1521-1530. PubMed ID: 33257979
[TBL] [Abstract] [Full Text] [Related]
6. Secondary acquisition of BCR-ABL1 fusion in de novo GATA2-mecom positive acute myeloid leukemia with subsequent emergence of a rare KMT2A-ASXL2 fusion.
Blackburn PR; Huang L; Dalovisio A; Pitel BA; Chen D; Oliveira JL; Wood AJ; Smadbeck JB; Johnson SH; Vasmatzis G; Haferlach C; Greipp PT; Hoppman NL; Ketterling RP; Baughn LB; Peterson JF
Cancer Genet; 2020 Feb; 241():67-71. PubMed ID: 31902694
[TBL] [Abstract] [Full Text] [Related]
7. evi1 triggers metabolic reprogramming associated with leukemogenesis and increases sensitivity to L-asparaginase.
Saito Y; Sawa D; Kinoshita M; Yamada A; Kamimura S; Suekane A; Ogoh H; Matsuo H; Adachi S; Taga T; Tomizawa D; Osato M; Soga T; Morishita K; Moritake H
Haematologica; 2020 Aug; 105(8):2118-2129. PubMed ID: 31649131
[TBL] [Abstract] [Full Text] [Related]
8. evi1 induces autophagy to promote drug resistance via regulation of ATG7 expression in leukemia cells.
Niu Y; Yang X; Chen Y; Jin X; Li L; Guo Y; Li X; Xie Y; Zhang Y; Wang H
Carcinogenesis; 2020 Jul; 41(7):961-971. PubMed ID: 31593983
[TBL] [Abstract] [Full Text] [Related]
9. The secreted protein acidic and rich in cysteine is a critical mediator of cell death program induced by WIN/TRAIL combined treatment in osteosarcoma cells.
Notaro A; Sabella S; Pellerito O; Vento R; Calvaruso G; Giuliano M
Int J Oncol; 2016 Mar; 48(3):1039-44. PubMed ID: 26698404
[TBL] [Abstract] [Full Text] [Related]
10. Combined Ablation and Radiation Therapy of Spinal Metastases: A Novel Multimodality treatment Approach.
Greenwood TJ; Wallace A; Friedman MV; Hillen TJ; Robinson CG; Jennings JW
Pain Physician; 2015 Nov; 18(6):573-81. PubMed ID: 26606009
[TBL] [Abstract] [Full Text] [Related]
11. A modified γ-retrovirus vector for X-linked severe combined immunodeficiency.
Hacein-Bey-Abina S; Pai SY; Gaspar HB; Armant M; Berry CC; Blanche S; Bleesing J; Blondeau J; de Boer H; Buckland KF; Caccavelli L; Cros G; De Oliveira S; Fernández KS; Guo D; Harris CE; Hopkins G; Lehmann LE; Lim A; London WB; van der Loo JC; Malani N; Male F; Malik P; Marinovic MA; McNicol AM; Moshous D; Neven B; Oleastro M; Picard C; Ritz J; Rivat C; Schambach A; Shaw KL; Sherman EA; Silberstein LE; Six E; Touzot F; Tsytsykova A; Xu-Bayford J; Baum C; Bushman FD; Fischer A; Kohn DB; Filipovich AH; Notarangelo LD; Cavazzana M; Williams DA; Thrasher AJ
N Engl J Med; 2014 Oct; 371(15):1407-17. PubMed ID: 25295500
[TBL] [Abstract] [Full Text] [Related]
12. Symptomatic bone marrow involvement in breast cancer--clinical presentation, treatment, and prognosis: a single institution review of 22 cases.
Kopp HG; Krauss K; Fehm T; Staebler A; Zahm J; Vogel W; Kanz L; Mayer F
Anticancer Res; 2011 Nov; 31(11):4025-30. PubMed ID: 22110237
[TBL] [Abstract] [Full Text] [Related]
13. Angiopoietin1 contributes to the maintenance of cell quiescence in evi1(high) leukemia cells.
Ichihara E; Kaneda K; Saito Y; Yamakawa N; Morishita K
Biochem Biophys Res Commun; 2011 Dec; 416(3-4):239-45. PubMed ID: 22033412
[TBL] [Abstract] [Full Text] [Related]
14. Acute promyelocytic leukemia relapsing as secondary acute myelogenous leukemia with translocation t(3;21)(q26;q22) and RUNX1-mds1-evi1 fusion transcript.
Park TS; Choi JR; Yoon SH; Song J; Kim J; Kim SJ; Kwon O; Min YH
Cancer Genet Cytogenet; 2008 Dec; 187(2):61-73. PubMed ID: 19027486
[TBL] [Abstract] [Full Text] [Related]
15. Is it important to decipher the heterogeneity of "normal karyotype AML"?
Nimer SD
Best Pract Res Clin Haematol; 2008 Mar; 21(1):43-52. PubMed ID: 18342811
[TBL] [Abstract] [Full Text] [Related]
16. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of mds1-evi1, PRDM16 or SETBP1.
Ott MG; Schmidt M; Schwarzwaelder K; Stein S; Siler U; Koehl U; Glimm H; Kühlcke K; Schilz A; Kunkel H; Naundorf S; Brinkmann A; Deichmann A; Fischer M; Ball C; Pilz I; Dunbar C; Du Y; Jenkins NA; Copeland NG; Lüthi U; Hassan M; Thrasher AJ; Hoelzer D; von Kalle C; Seger R; Grez M
Nat Med; 2006 Apr; 12(4):401-9. PubMed ID: 16582916
[TBL] [Abstract] [Full Text] [Related]
17. t(3;21)(q26;q22) in myeloid leukemia: an aggressive syndrome of blast transformation associated with hydroxyurea or antimetabolite therapy.
Yin CC; Cortes J; Barkoh B; Hayes K; Kantarjian H; Jones D
Cancer; 2006 Apr; 106(8):1730-8. PubMed ID: 16532439
[TBL] [Abstract] [Full Text] [Related]
18. Arsenic trioxide as a treatment for myelodysplastic syndrome.
Sekeres MA
Curr Hematol Rep; 2005 Jan; 4(1):59-63. PubMed ID: 15610661
[TBL] [Abstract] [Full Text] [Related]
19. evi1 abrogates interferon-alpha response by selectively blocking PML induction.
Buonamici S; Li D; Mikhail FM; Sassano A; Platanias LC; Colamonici O; Anastasi J; Nucifora G
J Biol Chem; 2005 Jan; 280(1):428-36. PubMed ID: 15519999
[TBL] [Abstract] [Full Text] [Related]
20. A unique AML1 (CBF2A) rearrangement, t(1;21)(p32;q22), observed in a patient with acute myelomonocytic leukemia.
Cherry AM; Bangs CD; Jones P; Hall S; Natkunam Y
Cancer Genet Cytogenet; 2001 Sep; 129(2):155-60. PubMed ID: 11566347
[TBL] [Abstract] [Full Text] [Related]
[Next]
